A group of Congressional Democratic leaders complained about a FDA proposal that would limit when drug and device companies can add warnings to product labels.
In a letter to Commissioner Andrew von Eschenbach, several lawmakers said current FDA rules give companies latitude to make needed changes. They said the new policy is restrictive and comes "at the expense of consumers and violates the mission of the FDA."
For more, go NJ.com here.
